Efanesoctocog alfa

7 月 31 日，赛诺菲发布 2025 年 Q2 和上半年财报：第二季度，销售额为 99.94 亿欧元（约 110 亿美元），增长 10.1%（按固定汇率计算，下同）；上半年，销售额为 198.89 亿欧元（约 219 亿美元），增长 9.9%。汇率按 2015 H1 平均汇率计算，1 欧元=1.1004 美元。从地区来看，上半年：美国市场收入最多，为 95.35 亿欧元，增长 16.4%；欧洲市场销售额为 41.44 亿欧元，增长 1.8%；中国市场收入为 13.88 亿欧元，增长 0.1%。截图来源：赛诺菲财报，下同制药业务新上市的 8 款药品，Q2 收入 8.97 亿欧元，增长 39.8%；上半年收入 17.44 亿欧元，增长 41.7%。其中，ALTUVIIIO（A 型血友病药物）增速最快，Q2 销售额为 2.91 亿欧元，增长 91.8%；上半年销售额为 5.42 亿欧元，增长 95.4%。自免药物领域，Dupixent（度普利尤单抗）上半年销售额为 73.12 亿欧元（约 80 亿美元），增长 20.7%。全球销售额的增长得益于所有获批适应症持续强劲的需求，包括特应性皮炎 (AD)、哮喘、伴有鼻息肉的慢性鼻窦炎、嗜酸性食管炎、结节性痒疹、慢性自发性荨麻疹、慢性阻塞性肺病 (COPD) 和大疱性类天疱疮。其它产品中，增速在 10% 以上的药物有三款，分别为：Lantus（甘精胰岛素），上半年销售额为 8.76 亿欧元，增长 17.7%；Toujeo（新一代基础胰岛素），上半年销售额为 6.92 亿欧元，增长 10.3%；Alprolix（B 型血友病药物），上半年销售额为 3.05 亿欧元，增长 13.7%。疫苗业务疫苗业务，Q2 销售额为 12.14 亿欧元，增长 10.3%；上半年销售额为 25.40 亿欧元，增长 10.9%。其中，脊髓灰质炎/百日咳/乙型流感嗜血杆菌 (PPH) 基础疫苗和加强疫苗是主力军，上半年创造了 13.61 亿欧元的收入，占到了疫苗收入的一半以上。管线进展赛诺菲目前在四大主要疾病领域（免疫学、罕见病、神经病学以及肿瘤学）和疫苗领域拥有 82 个在研项目，其中包括 40 个潜在的新药和疫苗。2025 下半年有望迎来多项里程碑进展。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range Paris, July 31, 2025 Q2 sales growth of 10.1% at CER1 and business EPS2 of €1.59 Pharma launches increased sales by 39.8%, reaching €0.9 billion, driven by ALTUVIIIO Dupixent sales increased by 21.1% to €3.8 billion, supported by the COPD launch Vaccines sales increased by 10.3% to €1.2 billion Research and Development expenses were €1.9 billion, up 17.7% Selling, general and administrative expenses were €2.3 billion, up 7.8% Business EPS was €1.59, up 8.3% at CER and up 1.9% reported; IFRS EPS was €3.24 Pipeline progress Three regulatory approvals: Dupixent BP (US), Sarclisa NDMM, TE (EU), and MenQuadfi meningitis (US) Three phase 3 readouts, incl. itepekimab COPD (one met primary endpoint/one did not); positive SP0087 in rabies prevention Seven regulatory designations, including orphan and fast track, in rare diseases, neurology, and oncology Capital allocation Sanofi and CD&R closed the Opella transaction, creating an independent global consumer healthcare leader Acquisitions completed: Blueprint, in rare diseases/immunology, and Dren Bio’s DR-0201, early-stage pipeline in immunology Acquisitions announced: Vigil, in Alzheimer’s disease, and Vicebio, in respiratory vaccines, adding to the early-stage pipeline3 Sustainability Sanofi ranked the world’s tenth most sustainable company and number one in Pharmaceuticals & Biotechnology by TIME Guidance In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a low double-digit percentage at CER (before share buyback), now including all expenses from newly acquired businesses4 Sanofi intends to complete its €5 billion share buyback program in 2025. 80.3% has been repurchased to date Paul Hudson, Chief Executive Officer: “We delivered strong performance in Q2 with 10.1% sales growth. Our nine newly launched medicines and vaccines grew by 47.3%. Eight years after market introduction, Dupixent grew by more than 20%, supported by the COPD launch. Based on strong sales performance in H1, we are refining our 2025 sales guidance to the upper end of our previous range. At the same time, we confirm our guidance of a strong business EPS rebound, which now includes all expenses from newly acquired businesses. Our pipeline continues to make progress despite the mixed results with itepekimab in COPD. We are progressing the data analysis and once finished, we will discuss with regulatory authorities. We remain steadfast in our dedication to bringing new medicines and vaccines to patients. We eagerly anticipate several important phase 3 data readouts in the second half of the year, including amlitelimab in atopic dermatitis and tolebrutinib in primary progressive multiple sclerosis. Earlier in July, we successfully closed the acquisition of Blueprint in rare diseases, and we are anticipating the closing of the Vigil acquisition in neurology during Q3. Sanofi will remain focused on strategically redeploying capital towards growth and differentiated science with attractive financial returns. We continue to advance our strategy as an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth.” Q2 2025 Change Change at CER H1 2025 Change Change at CER IFRS net sales reported €9,994m +6.0% +10.1% €19,889m +8.3% +9.9% IFRS net income reported €3,939m +253.9% — €5,812m +158.8% — IFRS EPS reported €3.24 +264.0% — €4.74 +163.3% — Free cash flow5 €1,429m +65.8% — €2,458m +474.3% — Business operating income €2,461m -2.4% +3.3 % €5,363m +8.6% +10.8% Business net income €1,940m -0.6% +5.1 % €4,152m +7.6% +9.8% Business EPS €1.59 +1.9% +8.3% €3.39 +9.7% +12.0% 1 Changes in net sales are at constant exchange rates (CER) unless stated otherwise (definition in Appendix 9). 2 To facilitate an understanding of operational performance, Sanofi comments on the business net income, a non-IFRS financial measure (definition in Appendix 9). The income statement is in Appendix 3 and a reconciliation of net income as reported under IFRS to business net income is in Appendix 4. 3 Subject to closing conditions detailed overleaf. 4 Applying July 2025 average currency exchange rates, the currency impacts are estimated at around -4% on sales and at around -6% on business EPS. 5 Free cash flow is a non-IFRS financial measure (definition in Appendix 9). Attachment Press release